Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations
IMAGE: The trial results will be reported at the ESMO World Congress on Gastrointestinal Cancer 2019 by principal investigator Scott Kopetz, M.D., associate professor of Gastrointestinal Medical Oncology. view more Credit: MD Anderson Cancer Center BARCELONA — The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal…